Auto logout in seconds.
Continue LogoutDisparities in cancer treatment and survivorship persist across racial, socioeconomic, geographic, and other demographic lines. Addressing these inequities is vital for organizations dedicated to improving patient outcomes in cancer care. Improving equity also requires acknowledging that unconscious bias may exist in systems, processes, and interactions. Advisory Board interviewed clinicians who are working towards more equitable patient outcomes to identify six key areas of focus for advancing health equity:
This self-assessment tool is designed to help organizations evaluate their current practices and identify opportunities for improvement. Each page of the tool includes detailed subcategories with descriptions of foundational, progressing, and best practice approaches within each focus area. Discussion questions are provided to help your team reflect on where your organization currently stands and envision actionable steps to strengthen your health equity efforts. While working through this tool, consider what changes you might make to advance your organization’s health equity practices.
This research is based on Advisory Board interviews and analysis. Six clinicians who are advancing health equity in cancer care within their organizations informed this tool by sharing their practices and approaches.
Data may inform current course of action and serve as a real-time warning system when equity goals are not being met. Best-in-class use of data includes both consistency in gathering data, as well as a strategy to use the data to take action where appropriate.
| Foundational | Progressing | Best practice | |
|---|---|---|---|
| Patient treatment progression | Clinicians monitor individual patient treatment progression but lack a system for analyzing it across all patients | Data around treatment progression milestones is sometimes available but may not be easily accessible or real time | Organization has a system that shows real time when treatment milestones are missed to allow for follow-up |
| Visibility of outcomes data by common inequities | Clinicians have access to some outcomes data, but it is not consistently broken down along equity lines | Clinicians have access to outcomes data that is broken down along equity lines; data is not in an easily accessible or usable format | Clinicians have easy access to frequently updated outcomes data broken down to specifically examine inequities |
| Patient social determinants of health (SDoH) tracking | Clinicians or other staff may be aware of patient SDoH but do not track these needs in a standard way | All patients are screened for SDoH factors, but there may not be a robust follow-up process when needs are identified | All patients are screened for SDoH, and the organization has dedicated staff time to connect patient to relevant resources |
Social determinants of health (SDoH) Nonmedical factors affecting health, like socioeconomic status and geographic location1 |
Ongoing advancements in oncology research can make it difficult for clinicians to stay up-to-date and to ensure that care is consistently aligned with the highest quality guidance. This challenge is greater for cancer patients with comorbidities, as their treatment must consider overlapping conditions and potential drug interactions. Creating avenues for collaboration and continuing education among clinicians can potentially help ensure all patients — with or without comorbidities — receive high quality care.
| Foundational | Progressing | Best practice | |
|---|---|---|---|
| Continuing education for clinicians | Clinicians keep up-to-date on clinical best practices on their own as new research and guidelines are published | The organization offers clinicians some resources for keeping up with advances, but still relies primarily on clinician initiative | The organization provides clinicians with resources like conferences, trainings, and protected time to stay updated on clinical best practices |
| Multi-specialty collaboration | When patients present with comorbidities, clinicians refer care for areas outside their specialty | Clinicians collaborate informally with other specialties as needed to ensure aligned treatment across comorbidities | Systems or forums exist (e.g., multi-specialty forums) to consistently discuss treatment plans, comorbidities, and patient progress when appropriate |
| Prescription drug interaction monitoring | Clinician is responsible for identifying potential drug interactions during patient consultations | Organizations have standardized protocols or tools to monitor potential drug interactions (e.g., EHR warnings or checklists) | The organization has dedicated staff (e.g., clinical pharmacists) to help monitor for drug interactions and advise on treatment protocols |
Biomarker testing and precision medicine may allow cancer treatments to be tailored to the unique genetic and molecular characteristics of a patient’s tumor, which has the potential to improve patient outcomes. Expanding access to these tools can help address health disparities.
| Foundational | Progressing | Best practice | |
|---|---|---|---|
| Biomarker testing | Biomarker testing completed inconsistently, no standardized process for timely result integration and treatment | Biomarker testing performed consistently, but results may be inconsistently used due to delays, accessibility issues, or incorrect referrals | Biomarker testing is consistently performed; results are easily accessed by clinicians and used for timely treatment when applicable |
| Precision medicine and specialty care | Patients see a generalist or specialist based on factors like chance and geography, not clinical appropriateness | Specialists and generalists informally collaborate to ensure precision medicine cases get the right specialist input | There is a referral system or direct communication avenue to ensure access to precision medicine and specialist care |
| Access to clinical trials | Organization refers or enrolls eligible patients in clinical trials when the opportunity presents | Clinical trial enrollment is actively sought for all eligible patients, but the organization does not provide outreach or additional support | Organization invests staff time (e.g., a research coordinator) to foster patient confidence in clinical trials and enrolls all eligible patients |
Patients who have lower levels of health literacy or trust in healthcare may struggle to adhere to treatment plans. Creating systems for patient engagement can potentially help patients better understand their treatments and build trust with their providers, ultimately having the potential to lead to better adherence and better outcomes.
| Foundational | Progressing | Best practice | |
|---|---|---|---|
| Patient education and trust | Clinicians educate patients and build relationships with patients during appointments, as time allows | Organization has scaled resources (written or digital) with accessible language to ensure patients understand their treatment | Organization has members of the clinical team (e.g., clinic nurses or nurse navigators) who explain treatments, answer questions, and provide support to patients outside of appointments |
| Care navigation | Patients usually manage their own care journey, including making appointments, getting referrals, and consulting their clinicians about needs | Staff in other patient-facing roles (e.g., nurses, social workers, or administrative personnel) may assist patients in navigating the healthcare system as needed | Trained staff help patients by coordinating appointments, providing education, connecting to resources, and offering emotional support |
| Scheduling flexibility | Patient visits are scheduled in a timely manner where there are openings; time and location flexibility is limited | Efforts made to schedule visits promptly and consider patient convenience (e.g., grouping appointments), but flexibility in time and location is limited | Intentional efforts are made to schedule patients conveniently, (e.g., same-day imaging and consults) when possible |
Patients' nonclinical needs — which may include lack of stable housing, food insecurity, unreliable transportation, lack of childcare, inability to take time off at their job for treatments, and more — might prevent patients from being able to adhere to their treatment plans. Addressing these needs removes barriers to care and may ultimately improve outcomes.
| Foundational | Progressing | Best practice | |
|---|---|---|---|
| Referrals to outside organizations | Organization has identified community resources that meet non-clinical needs (e.g.,, housing, food, transportation); patients are given contact information when needed | Organization is building partnerships with community organizations and frequently refer patients when risk factors are identified
| Organization has strong partnerships with community organizations and has staff members (e.g., social workers or nurse navigators) to assist patients in making those connections
|
| Financial navigation | Basic financial navigation and guidance may be offered to patients, including general information about costs and insurance coverage
| Financial navigators help patients understand their insurance and treatment cost estimates
| Financial navigators help patients understand insurance and costs, work to obtain insurance coverage, and apply for financial or pharmaceutical assistance programs
|
1 Social Determinants of Health. CDC Public Health Professionals Gateway. November 13, 2025.
At Pfizer, we’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place.
Our unique resources allow us to do more for people. Using our global presence and scale, we’re able to make a difference in local communities and the world around us.
Pfizer supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. For more information, please visit www.pfizer.com.
This self-assessment tool is sponsored by Pfizer, an Advisory Board member organization. Representatives of Pfizer helped select the topics and issues addressed. Advisory Board experts maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.
To learn more, view our editorial guidelines.
This self-assessment tool is sponsored by Pfizer. Advisory Board experts maintained final editorial approval, and conducted the underlying research independently and objectively.
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Never miss out on the latest innovative health care content tailored to you.
This is for members only. Learn more.
Never miss out on the latest innovative health care content tailored to you.